Silexion Therapeutics Corp
SLXN · XNASCIK 2022416fmd_1EC25RB7AFASA7JMB5ZMH6G2QNManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 14 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total interest income | 0 | 0 | 0 |
| Net interest income | 0 | 0 | 0 |
| Research and development | 4 | 6 | 7 |
| Total operating expenses | 5 | 13 | 12 |
| Operating income | (5) | (13) | (12) |
| Interest expense | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | 4 | 0 |
| Income before taxes | (5) | (17) | (12) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (5) | (17) | (12) |
| Net income | (5) | (17) | (12) |
| Net income to common shareholders | 5 | 16 | 12 |